Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China, 510180.
Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Int J Med Sci. 2020 Mar 26;17(7):912-920. doi: 10.7150/ijms.40864. eCollection 2020.
: CC chemokine receptor 9 (CCR9) interacts with its exclusive ligand CCL25, resulting in promoting tumor progression and metastasis. However, the effect and mechanisms of CCR9 on lung adenocarcinoma distant metastasis remain largely unknown. To preliminary clarify the underlying mechanisms, we investigate the correlation between CCR9 and ALDH1A1cancer stem cells (CSCs), as well as the effect of CCR9 on the migration and invasion of CSCs. : Immunohistochemistry was performed to detect the expression of CCR9 in lung adenocarcinoma tissues. The correlations of CCR9 with distant metastasis and overall survival were investigated. Serial paraffin-embedded tissue blocks were used to detect ALDH1A1CSCs expression. The correlations between CCR9 expression and ALDH1A1CSCs were evaluated. We further studied the effect of CCR9/CCL25 on the migration and invasion of CSCs using transwell assays. : There were positive correlations between CCR9 expression and distant metastasis, as well as poor overall survival. Patients with high CCR9 expression were more likely to develop distant metastasis and demonstrated poorer overall survival than patients with low CCR9 expression. In addition, there was positive correlation between the expression of CCR9 and ALDH1A1 in the same tumor microenvironment. ALDH CSCs demonstrated enhanced expression of CCR9 than ALDH cells. Further transwell assays demonstrated that the numbers of CSCs migrated or invaded in response to CCL25 were more than that without CCL25 stimulation. Additional application of anti-CCR9 antibody reversed the CCL25-induced migration and invasion of CSCs. : In summary, our study demonstrated that CCR9/CCL25 promoted the migration and invasion of CSCs, which might contribute to distant metastasis and poor overall survival. Our findings provided evidence that CCR9/CCL25 could be used as novel therapeutic targets for lung adenocarcinoma.
: C 型凝集素趋化因子受体 9(CCR9)与其独特配体 CCL25 相互作用,从而促进肿瘤的进展和转移。然而,CCR9 对肺腺癌远处转移的影响和机制在很大程度上尚不清楚。为了初步阐明潜在的机制,我们研究了 CCR9 与 ALDH1A1 肿瘤干细胞(CSCs)之间的相关性,以及 CCR9 对 CSCs 迁移和侵袭的影响。 : 我们通过免疫组织化学检测了肺腺癌组织中 CCR9 的表达。研究了 CCR9 与远处转移和总生存的相关性。我们使用连续的石蜡包埋组织块来检测 ALDH1A1CSCs 的表达。评估了 CCR9 表达与 ALDH1A1CSCs 之间的相关性。我们进一步通过 Transwell 实验研究了 CCR9/CCL25 对 CSCs 迁移和侵袭的影响。 : CCR9 表达与远处转移和总生存不良呈正相关。高 CCR9 表达的患者比低 CCR9 表达的患者更容易发生远处转移,总生存较差。此外,在同一肿瘤微环境中,CCR9 表达与 ALDH1A1 的表达呈正相关。ALDH CSCs 比 ALDH 细胞表现出更高的 CCR9 表达。进一步的 Transwell 实验表明,CSCs 对 CCL25 的反应性迁移或侵袭数量多于没有 CCL25 刺激时的数量。额外应用抗 CCR9 抗体逆转了 CCL25 诱导的 CSCs 迁移和侵袭。 : 综上所述,我们的研究表明 CCR9/CCL25 促进了 CSCs 的迁移和侵袭,这可能导致远处转移和总生存不良。我们的研究结果为 CCR9/CCL25 可用作肺腺癌的新型治疗靶点提供了证据。